Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu

Biomarker/ALK Inhibitor Combinations in Treating Patients With Lung Cancer

Research Question:
How well does a combination of different biomarker/ALK inhibitors work in treating patients with stage IV lung cancer?

Basic Study Information

Purpose:
This National Cancer Institute (NCI)-NRG phase II trial studies how well a combination of different biomarker/ALK inhibitors work in treating patients with stage IV, ALK positive, non-squamous, non-small cell lung cancer.ALK inhibitors like lorlatinib, ceritinib, alectinib, brigatinib, ensartinib, and crizotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as pemetrexed, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether a combination of biomarker/ALK inhibitors or chemotherapy may work better in treating patients with lung cancer.

Location: University of Rochester Medical Center
Study Reference #: CLUN19117

Lead Researcher (Principal Investigator)

Lead Researcher:  Ronald Maggiore

Study Contact Information

Study Coordinator: Amy Jasek
Phone: (585) 273-1912
Email: Amy_Jasek@URMC.Rochester.edu

Additional Study Details

Return to Search